MicroRNA与弥漫大B淋巴瘤预后关系的系统综述和Meta分析

李璐; 董晓强; 李艳艳; 郭建全; 乔增杰; 王彤

doi:10.16462/j.cnki.zhjbkz.2018.05.018

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名

邮箱

手机号码

标题

留言内容

验证码

MicroRNA与弥漫大B淋巴瘤预后关系的系统综述和Meta分析

doi: 10.16462/j.cnki.zhjbkz.2018.05.018

1. 山西医科大学公共卫生学院卫生统计教研室, 山西太原 030001;
2. 山西医科大学公共卫生学院卫生检验教研室, 山西太原 030001

基金项目:

国家自然科学基金（81473073）

详细信息

作者简介:
李璐(1993-),女,山西原平人,在读硕士研究生。主要研究方向:多元统计方法及医学应用。

中图分类号: R733.41
计量
- 文章访问数: 279
- HTML全文浏览量: 38
- PDF下载量: 19
- 被引次数: 0
出版历程
- 收稿日期: 2017-12-13
- 修回日期: 2018-03-14

A systematic review and Meta-analysis on the relationship between microRNAs and prognosis in diffuse large B-cell lymphoma

1. Department of Health Statistics, School of Public Health, Shanxi Medical University, Taiyuan 030001, China;
2. Department of Hygiene Detection, School of Public Health, Shanxi Medical University, Taiyuan 030001, China

摘要

摘要: 目的综合分析不同的微小RNA （microRNAs，miRs）对弥漫大B淋巴瘤（diffuse large B cell lymphoma，DLBCL）的预后价值。方法计算机检索2007年1月~2017年7月收录在万方数据库、维普中文科技期刊全文数据库、中国期刊全文数据库、PubMed数据库和Embase数据库的相关文献，筛选后采用Stata 12.0进行Meta分析。结果最终纳入30篇文献，2 574研究对象。综合分析发现，miR-21的低表达降低了DLBCL患者的无复发生存期（relapse free survival，RFS）（HR=0.61，95% CI：0.40~0.94，P=0.024）；miR-155的高表达降低了DLBCL患者的无进展生存期（progress free survival，PFS）（HR=2.50，95% CI：1.54~4.06，P<0.001）；miR-222的高表达降低了DLBCL患者的PFS （HR=2.33，95% CI：1.53~3.57，P<0.001）。结论基于所有分析结果可知，miR特别是miR-21，miR-222和miR-155是影响DLBCL的RFS和PFS重要预后因子。
- 淋巴瘤,非霍奇金 /
- 预后 /
- meta分析
Abstract: Objective To comprehensively analyze the prognostic value of different microRNAs (miRs) in diffuse large B-cell lymphoma(DLBCL).Methods A computerized retrieval was carried out by using Wanfang data,VIP databases,CNKI, PubMed and Embase databases to collect the relevant literatures published from January 2007 to July 2007.By screening, Meta-analysis was performed with Stata 12.0 software.Results Thirty literatures comprised 2 574 cases were included. Comprehensive analysis revealed that decreased expression of miR-21 was associated with shorter relapse-free survival(RFS)in DLBCL(HR=0.61,95% CI:0.40-0.94, P=0.024). Increased expression of miR-155 was associated with shorter progression-free survival(PFS)(HR=2.50,95% CI:1.54-4.06, P<0.001). Increased expression of miR-222 was associated with shorter PFS(HR=2.33,95% CI:1.53-3.57, P<0.001).Conclusions According to the results, it can be concluded that miRs especially miR-21,miR-155 and miR-222 are valuable prognostic predictors in DLBCL of recurrence free survival and progression free survival period.
- Non-hodgkin's lymphoma /
- Prognosis /
- Meta-analysis